Latest Manufacturing News

Australian Vanadium Limited reports significant progress across its vertically integrated vanadium strategy, with key project milestones, government approvals, and promising energy storage developments positioning it for growth.

Titomic Limited advances its strategic U.S. footprint with a new Huntsville facility set to open in June 2025, securing major defense collaborations and expanding commercial momentum in additive manufacturing.

BirdDog Technology reported a slight 4.1% decline in Q3 FY25 sales to A$3.6 million while progressing strongly on its next-generation product roadmap and implementing significant cost reductions.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Fluence Corporation reported a robust Q1 2025 with revenue surging 64.5% year-over-year, driven by the Ivory Coast Addendum project, while EBITDA turned positive for the first time in over a year. The company maintains its full-year guidance despite tariff uncertainties.

Weebit Nano has marked a pivotal quarter by achieving automotive-grade AEC-Q100 qualification for its ReRAM technology, advancing integration with semiconductor giant onsemi, and securing a robust cash position to fuel growth.

Visionflex Group Limited reported a net cash outflow of AUD 1.34 million for Q1 2025, maintaining liquidity through convertible note facilities that extend funding runway to over two quarters.

NOVONIX has signed a definitive agreement to acquire a large parcel in Chattanooga for a new synthetic graphite facility, significantly boosting its production capacity and local employment.

CurveBeam AI reported a robust 40% increase in purchase orders during Q3 FY25 and secured a non-binding A$18 million vendor financing term sheet, positioning the company for cashflow positivity in Q4.

CurveBeam AI Limited reported a $4.367 million net operating cash outflow for Q3 2025 but anticipates a significant improvement in cash flow driven by device installations and customer receipts, with no immediate plans for capital raising.

Amplia Therapeutics has completed recruitment early for its Phase 2a ACCENT trial in advanced pancreatic cancer, reporting encouraging interim results and advancing a second trial with FDA-backed protocol changes.

Ecofibre Limited reported a $2.2 million operating cash outflow in 3Q25 with total cash at $1.3 million, highlighting mixed progress across its business units and a pressing need to monetise assets to sustain operations.